Untargeted metabolomics uncovers prime pathways linked to antibacterial action of citral against bacterial vaginosis-causing : An and study.

Global increase in recurrence of bacterial vaginosis (BV) and worrisome rise in antimicrobial resistance pose an urgent call for new/novel antibacterial agents. In light of the circumstance, the present study demonstrates the and antibacterial activity of a phytochemical citral, with a particular emphasis to elucidate its mechanistic action against -a potential cause of BV. Out of 21 phytochemicals screened initially against , citral was envisaged to be a phenomenal antibacterial agent showing MIC and MBC at 128 μg/mL. Citral's rapid killing ability was revealed by a time-killing kinetics assay supported by CFU, signifying that it completely killed the given inoculum of planktonic cells within 60 min. Further, citral was found to exhibit 1 min contact-killing efficacy together with mature-biofilm disintegrating ability at increasing MICs. To further understand the molecular action of citral, investigations such as ROS estimation, PI staining and intracellular protein release assay were performed, which demonstrated that citral deteriorated the membrane integrity of . , a simple invertebrate model used to evaluate citral's non-toxic and antibacterial activity , demonstrates that citral completely restored the larvae from infection. The metabolite level investigation using LC-MS revealed that citral had negative impact on biotin metabolism (., biotin), spermidine metabolism (., 5'-methylthioadenosine and spermidine) and nucleotide metabolism (., guanine, adenine and uridine). Since that biotin is associated with seven different metabolic pathways, it is conceivable that citral could target biotin biosynthesis or its metabolism and as a result, disrupt other metabolic pathways, such as lipid and fatty acid synthesis, which is essential for the creation of cell membranes. Thus, the current study is the first of its kind to delineate the promising and antibacterial efficacy of citral and decipher its plausible antibacterial action mechanism through metabolomic approach, which concomitantly emphasizes citral as a viable natural therapeutic alternative to manage and control BV.